Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.
Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.
Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.
Massimo Cristofanilli, MD, discusses emerging treatment approaches for patients with estrogen receptor-positive/HER2-negative breast cancer with an ESR1 mutation.
Early dose reductions in a common adjuvant chemotherapy regimen were associated with inferior survival outcomes in a retrospective study of women with intermediate- to high-risk breast cancer.
An updated biologics license application has been submitted to the FDA for eflapegrastim for the management of chemotherapy-induced neutropenia.
The FDA has issued a draft guidance to propose labeling recommendations, including a boxed warning, to breast implant manufacturers in an effort to help patients understand the benefits and risks of these devices.
Armando E. Giuliano, MD, a 2018 OncLive Giants of Cancer Care® award winner in Surgical Oncology, disrupted the treatment landscape for early breast cancer when he introduced sentinel lymph node biopsy. The result led to improved quality of life and reduced the need for radical breast cancer procedures for many patients.
Bernard Fisher, MD, a world-renowned physician/scientist and the chair of the National Surgical Adjuvant Breast and Bowel Project for more than 27 years, has died at the age of 101.
Gretchen G. Kimmick, MD, MS, discusses the management of patients with early-stage hormone receptor–positive, HER2-negative breast cancer.